Vitiligo, alopecia more likely in GVHD when donor is female and recipient is maleSeptember 10, 2014Myelodysplastic SyndromeTransfusion MedicineCMLCellular Therapy
Molecular monitoring and minimal residual disease in the management of chronic myelogenous leukemiaMay 27, 2014Patient & Survivor CareCML
Omacetaxine for chronic or accelerated phase CML in patients with resistance or intolerance to TKIsSeptember 3, 2013CMLBusiness of Medicine
